Document is current
Any future updates will be listed below
-
Authors
Tang, Li-Bo https://orcid.org/0000-0002-4870-4408
Peng, Ying-Long https://orcid.org/0000-0002-7162-4422
Chen, Ji
Li, Jia-Ting
Zheng, Mei-Mei https://orcid.org/0000-0002-3493-7139
Wu, Lv
Lu, Chang
Wei, Xue-Wu
Cai, Dong-Xuan
Guo, Zhi
Ren, Zi-Rui
Lv, Si-Di
Deng, Yu
Chen, Zhi-Hong
Xu, Chong-Rui https://orcid.org/0000-0002-3474-2809
Zhou, Qing https://orcid.org/0000-0002-0478-176X
- License Information
-
More Information
Article History
Accepted: 5 May 2025
First Online: 9 June 2025
Competing interests
: C.-R.X. has acted as a consultant and/or advisor of Allist Pharmaceuticals, AstraZeneca, Avistone, BeiGene, Bristol–Myers Squibb, Burning Rock Biotech, CStone Pharmaceuticals, Dizal Pharma, Geneplus, MSD, Pfizer, Roche, SciClone, Takeda and Zhengda Tianqing Pharmaceutical Group. Q.Z. has received honoraria from AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, MSD, Pfizer, Roche and Sanofi for consultancy and/or advisory work. The other authors declare no competing interests.
